S. Edgerton

677 total citations
8 papers, 560 citations indexed

About

S. Edgerton is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, S. Edgerton has authored 8 papers receiving a total of 560 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 4 papers in Radiology, Nuclear Medicine and Imaging and 3 papers in Molecular Biology. Recurrent topics in S. Edgerton's work include HER2/EGFR in Cancer Research (3 papers), Radiopharmaceutical Chemistry and Applications (2 papers) and Glioma Diagnosis and Treatment (2 papers). S. Edgerton is often cited by papers focused on HER2/EGFR in Cancer Research (3 papers), Radiopharmaceutical Chemistry and Applications (2 papers) and Glioma Diagnosis and Treatment (2 papers). S. Edgerton collaborates with scholars based in United States and Canada. S. Edgerton's co-authors include Ann D. Thor, Christopher C. Benz, Dan H. Moore, E. Tessa Hedley‐Whyte, David N. Louis, David F. Stern, Michael P. DiGiovanna, Brian H. Mayall, Jacques Landry and Eileen Hickey and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

S. Edgerton

8 papers receiving 545 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S. Edgerton United States	6	292	269	152	118	74	8	560
Emily Tarco United States	14	346 1.2×	332 1.2×	145 1.0×	149 1.3×	47 0.6×	19	620
Rena D. Callahan United States	6	389 1.3×	333 1.2×	125 0.8×	143 1.2×	22 0.3×	12	629
Rosa Conforti France	14	332 1.1×	255 0.9×	48 0.3×	165 1.4×	56 0.8×	29	757
Dan Lu China	9	203 0.7×	458 1.7×	94 0.6×	131 1.1×	35 0.5×	16	694
Nikia A. Laurie United States	10	485 1.7×	455 1.7×	45 0.3×	131 1.1×	59 0.8×	12	756
Frank Herting Switzerland	13	232 0.8×	318 1.2×	196 1.3×	100 0.8×	178 2.4×	28	712
Oriol Arpí Spain	15	376 1.3×	359 1.3×	64 0.4×	149 1.3×	26 0.4×	24	710
L. C. Padhy India	6	490 1.7×	530 2.0×	267 1.8×	151 1.3×	21 0.3×	11	890
Kim M. Dulski United States	9	306 1.0×	275 1.0×	90 0.6×	126 1.1×	24 0.3×	9	582
Cathy C. Zhang United States	11	196 0.7×	288 1.1×	61 0.4×	91 0.8×	23 0.3×	13	464

Countries citing papers authored by S. Edgerton

Since Specialization

Citations

This map shows the geographic impact of S. Edgerton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Edgerton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Edgerton more than expected).

Fields of papers citing papers by S. Edgerton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Edgerton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Edgerton. The network helps show where S. Edgerton may publish in the future.

Co-authorship network of co-authors of S. Edgerton

This figure shows the co-authorship network connecting the top 25 collaborators of S. Edgerton. A scholar is included among the top collaborators of S. Edgerton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Edgerton. S. Edgerton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Edgerton, S., Kirsten Vang Nielsen, Ann D. Thor, et al.. (2009). Thymidilate synthase (TS), thymidine phosphorylase (TP), dihydropyrimidine dehydrogenase (DPD), and dihydrofolate reductase (DHFR) as predictive markers of capecitabine efficacy in breast cancer patients. Journal of Clinical Oncology. 27(15_suppl). 11033–11033. 1 indexed citations

Berry, Donald A., Ann D. Thor, Scott D. Jewell, et al.. (2009). Benefits of Adding Paclitaxel to Adjuvant Doxorubicin/Cyclophosphamide Depending on HER2 & ER Status: Analysis of Tumor Tissue Microarrays and Immunohistochemistry in CALGB 9344 (Intergroup 0148).. Cancer Research. 69(24_Supplement). 606–606. 6 indexed citations

Tedesco, Karen L., Ann D. Thor, Douglas H. Johnson, et al.. (2004). Docetaxel Combined With Trastuzumab Is an Active Regimen in HER-2 3+ Overexpressing and Fluorescent In Situ Hybridization–Positive Metastatic Breast Cancer: A Multi-Institutional Phase II Trial. Journal of Clinical Oncology. 22(6). 1071–1077. 83 indexed citations

Thor, Ann D., S. Edgerton, Dan H. Moore, et al.. (2000). Activation (Tyrosine Phosphorylation) of ErbB-2 (HER-2/neu): A Study of Incidence and Correlation With Outcome in Breast Cancer. Journal of Clinical Oncology. 18(18). 3230–3239. 147 indexed citations

Millikan, Robert C., Barbara S. Hulka, Ann D. Thor, et al.. (1995). p53 mutations in benign breast tissue.. Journal of Clinical Oncology. 13(9). 2293–2300. 63 indexed citations

Louis, David N., S. Edgerton, Ann D. Thor, & E. Tessa Hedley‐Whyte. (1991). Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: A comparative study. Acta Neuropathologica. 81(6). 675–679. 123 indexed citations

Thor, Ann D., Christopher C. Benz, Dan H. Moore, et al.. (1991). Stress Response Protein (srp-27) Determination in Primary Human Breast Carcinomas: Clinical, Histologic, and Prognostic Correlations. JNCI Journal of the National Cancer Institute. 83(3). 170–178. 136 indexed citations

Louis, David N., et al.. (1990). PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA) IN HUMAN NERVOUS SYSTEM TUMORS. Journal of Neuropathology & Experimental Neurology. 49(3). 272–272. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact